Citizens analyst Reni J. Benjamin has reaffirmed a Market Outperform rating on Kura Oncology. The firm maintains a price target of $24 for the company's stock.

The rating and price target were reiterated in a recent analyst note. Kura Oncology is listed on the NASDAQ under the ticker symbol KURA.

Kura Oncology and Kyowa Kirin reported encouraging long-term results from the Phase 1/2 KOMET-007 trial evaluating ziftomenib in combination with intensive chemotherapy, 7+3, in newly diagnosed NPM1-m or KMT2A-r AML. The data demonstrated a 12-month overall survival rate of 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients. The companies announced that these results will be presented at the European Hematology Association 2026 Congress.

The trial results compare favorably to historical standard-of-care data with 7+3 alone. In the NPM1-m cohort, the composite complete remission rate was 96% with an objective response rate of 98%. The KMT2A-r cohort showed a 90% composite complete remission rate and a 92% objective response rate. Deep molecular responses were observed, with local CRc MRD-negativity rates of 85% in NPM1-m AML and 82% in KMT2A-r AML.

Key Efficacy Results

The durability of responses was encouraging, with median duration of complete response not reached for the NPM1-m AML cohort and 12 months for the KMT2A-r AML cohort. Median overall survival was not reached in either population at the time of data cut-off, following a median follow-up of 17.6 months for NPM1-m patients and 11.0 months for KMT2A-r patients.

Safety Profile

Ziftomenib 600 mg once-daily plus 7+3 was generally well tolerated, with no new or unexpected safety signals observed. The treatment showed low rates of ziftomenib-related cytopenias and minimal additive myelosuppression. There were no reports of Grade 4 differentiation syndrome or QTc prolongation events. A 60-day mortality rate of 2% was observed in NPM1-m patients.

"The updated results from the KOMET-007 trial provide important evidence supporting the safety and clinical activity of adding ziftomenib to intensive chemotherapy," said Amer Zeidan, M.B.B.S., M.H.S., Chief, Division of Hematologic Malignancies at Yale Cancer Center and Professor of Medicine at Yale School of Medicine. He noted that the regimen could represent a transformative therapeutic approach and may allow some patients to avoid allogeneic hematopoietic cell transplantation.

Kura Oncology plans to host a virtual investor event on June 12, 2026, at 8:00 a.m. ET to discuss these findings. The companies plan to publish the data in a peer-reviewed publication in the second half of 2026.